Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
J147 · 1 trial · 1 indication
Nature, frequency and severity of adverse events
12-lead electrocardiogram measurement
Changes in standard serum chemistry measures will be assessed.
Changes in standard hematology measures will be assessed.
Changes in standard urinalysis measures will be assessed.
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects. |
| Placebo | PLACEBO_COMPARATOR | Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours. |
| Name | Type | Description |
|---|---|---|
| J147 | DRUG | Single oral dose of J147 |
| Placebo | DRUG | Single oral dose of corn oil |
Inclusion Criteria: * Provide voluntarily agreement to participate in this study and signs an IRB/IEC-approved informed consent prior to performing any of the screening procedures * Healthy male subjects, between 18 to 50 years of age, inclusive, at the time of signing the informed consent; OR, Hea...
Top 20 of 24 competitors
J147 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied for its potential to address this neurological condition.
J147 is a small molecule being studied for Alzheimer's Disease. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is in Phase 1 development, with the focus of current research on safety, tolerability, and pharmacokinetics.
J147 is being developed by IQVIA Holdings, Inc., a company publicly traded under the ticker symbol IQV. IQVIA is conducting clinical research on this investigational drug for Alzheimer's Disease, with the drug currently in Phase 1 development.
J147 is in Phase 1 clinical development for Alzheimer's Disease. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in the early stages of clinical testing.
J147 has one completed Phase 1 clinical trial registered under NCT03838185, titled "Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147." This trial enrolled 64 participants in the United States and was a randomized, double-blind, placebo-controlled study.
J147 is not known to have any alternative names. It is a distinct investigational small molecule being developed for Alzheimer's Disease. The drug is currently in Phase 1 clinical development, with its safety and tolerability being evaluated in clinical trials.